8-K: Nu Skin Q3 Earnings Top Guidance, Eyes AI Wellness & India

Nu Skin Enterprises reported third-quarter revenue and earnings per share within its guidance range, with EPS at the high end, as it prepares for the launch of its Prysm iO intelligent wellness platform and expansion into India.

Summary

• Q3 2025 revenue was $364.2 million, a 15.3% decrease year-over-year, or an 11.5% decrease excluding Mavely 2024 revenue.
• Q3 2025 diluted earnings per share (EPS) was $0.34, compared to $0.17 in the prior-year quarter, landing at the high end of guidance.
• Customer count decreased by 10% to 746,256, Paid Affiliates decreased by 13% to 130,096, and Sales Leaders decreased by 19% to 31,150 year-over-year.
• Gross Margin improved to 70.5% from 70.1% in the prior-year quarter, and Operating Margin increased to 5.9% from 4.2%.
• The Latin America region delivered strong, double-digit year-over-year growth.
• The company is preparing for a limited sales leader preview of its Prysm iO intelligent wellness platform in late Q4 2025, with a broader sales leader availability and full consumer launch in 2026.
• Pre-market opening activities for expansion into India are scheduled for November 2025, with a formal launch anticipated in the second half of 2026.
• Q4 2025 revenue is projected to be between $365 million and $400 million, with EPS in the range of $0.25 to $0.35.
• Full-year 2025 revenue is projected at $1.48 billion to $1.51 billion, and EPS at $3.15 to $3.25 (adjusted EPS of $1.25 to $1.35).

Sentiment

Score: 6

Explanation: While the company met its Q3 guidance and showed operational improvements in margins, the underlying business metrics (revenue, customers, affiliates, sales leaders) experienced significant year-over-year declines. The sentiment is cautiously optimistic due to clear strategic initiatives (Prysm iO, India expansion) that aim to drive future growth, but these are forward-looking and carry execution risks.

Positives

• Q3 2025 diluted EPS of $0.34 was at the high end of the company's guidance range.
• Gross Margin improved to 70.5% in Q3 2025 from 70.1% in Q3 2024.
• Operating Margin expanded to 5.9% in Q3 2025 from 4.2% in Q3 2024.
• The Latin America region achieved strong, double-digit year-over-year growth.
• Sequential growth was observed in several reporting segments.
• The company is preparing for the limited introduction of Prysm iO, an AI-powered intelligent wellness platform, in late Q4 2025, with a full consumer launch in 2026.
• Pre-market opening activities for expansion into India are planned for November 2025, with a formal launch in the second half of 2026.
• Net cash position expanded due to operational discipline.

Negatives

• Total revenue declined by 15.3% to $364.2 million in Q3 2025 compared to $430.1 million in Q3 2024.
• Customer count decreased by 10% to 746,256 year-over-year.
• Paid Affiliates decreased by 13% to 130,096 year-over-year.
• Sales Leaders decreased by 19% to 31,150 year-over-year.
• Significant revenue declines were observed across most regions, including Mainland China (-19.8%), South Korea (-22.1%), and Nu Skin Americas (-17.1%).
• Rhyz Other segment revenue declined substantially by 81.4% year-over-year.
• Full-year 2025 revenue guidance was narrowed, reflecting ongoing market challenges.

Risks

• Any failure of current or planned initiatives or products to generate sustained interest among the sales force and customers, or to generate sponsoring and selling activities.
• Risk that direct selling laws and regulations in any markets, including the United States and Mainland China, may be modified, interpreted, or enforced in a manner that negatively impacts the business model, revenue, sales force, or operations.
• Global economic conditions and events.
• Future tax-planning initiatives, prospective or retrospective increases in duties or tariffs, adverse results of tax audits, or unfavorable changes to tax laws.
• Competitive pressures in the company's markets.
• Impact of epidemics or other crises, and related disruptions, on the business.
• Adverse publicity related to the company's business, products, industry, or any legal actions or complaints.
• Political, legal, tax, and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets.
• Uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment.
• Risk of foreign-currency fluctuations and their currency translation impact on the business.
• Uncertainties regarding the future financial performance of acquired businesses.
• Risks related to accurately predicting, delivering, or maintaining sufficient quantities of products, and increased risk of inventory write-offs if demand is over-forecasted or strategies change.
• Regulatory risks associated with products, potentially requiring claim modifications or inhibiting sales/import if products are determined to be medical devices or cannot be registered timely.

Future Outlook

The company projects Q4 2025 revenue between $365 million and $400 million, with EPS in the range of $0.25 to $0.35. For the full year 2025, revenue is projected at $1.48 billion to $1.51 billion, and EPS at $3.15 to $3.25 (adjusted EPS $1.25 to $1.35). Strategic initiatives include the limited introduction of the Prysm iO intelligent wellness platform in late Q4 2025, with a full consumer launch in 2026, and pre-market opening activities in India in November 2025, leading to a formal launch in the second half of 2026. These initiatives are expected to stimulate growth in nutritional supplements and drive customer lifetime value.

Management Comments

• Ryan Napierski, Nu Skin president and CEO, stated, "We are pleased with our third quarter results, which were in line with expectations, as we continue to navigate a challenging macro environment while preparing for the introduction of our intelligent wellness platform."
• Napierski added, "Through disciplined execution and operational efficiency, we delivered earnings per share at the high end of our guidance range."
• Napierski highlighted, "There is growing excitement and energy for the upcoming launch of our Prysm iO intelligent wellness platform and our expansion into India – two pivotal milestones that will accelerate our vision to become the world’s leading intelligent beauty and wellness company."
• Napierski believes, "Our AI-powered wellness assessment platform will stimulate growth in our nutritional supplements business by providing personalized product recommendations and subscriptions to drive customer lifetime value."
• James D. Thomas, chief financial officer, commented, "We continue to realize the benefits of our operational discipline with continued improvements in gross margin and further expansion of our net cash position."
• Thomas also noted, "Looking ahead, we are narrowing our revenue and earnings guidance based on our year-to-date performance."

Industry Context

The company operates within a "challenging macro environment," a common theme across many consumer-facing industries. Its strategic focus on an AI-powered intelligent wellness platform (Prysm iO) and expansion into India aligns with broader industry trends towards personalized health solutions, digital engagement, and tapping into high-growth emerging markets. The direct selling model, which Nu Skin utilizes, continues to face scrutiny and competitive pressures, necessitating innovation to maintain and grow its sales force and customer base.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Potential for future value creation through new product launches and market expansion, but current declines in revenue and sales force metrics may cause concern. Dividend payments and stock repurchases indicate a return of capital.
• Employees/Sales Force (Paid Affiliates, Sales Leaders): Decreases in paid affiliates and sales leaders suggest challenges in the direct selling model, potentially impacting their earnings and engagement. New product launches like Prysm iO and market expansion into India aim to re-energize and provide new growth opportunities.
• Customers: Introduction of Prysm iO aims to enhance customer experience with personalized recommendations and subscriptions, potentially increasing customer lifetime value.
• Suppliers: Rhyz Manufacturing showed revenue growth, indicating stable or increased demand for manufacturing services, potentially benefiting suppliers in that segment.

Next Steps

• Limited sales leader preview of the Prysm iO intelligent wellness platform in late Q4 2025.
• Broader sales leader availability and full consumer launch of Prysm iO in 2026.
• Pre-market opening activities in India in November 2025.
• Formal launch in India in the second half of 2026.
• Conference call with the investment community on November 6, 2025, at 5 p.m. (ET).

Key Dates

Recommendation

Nu Skin reported Q3 results in line with expectations, with EPS at the high end of guidance, and demonstrated operational improvements in gross and operating margins. However, the core business metrics, including overall revenue, customer count, paid affiliates, and sales leaders, experienced significant year-over-year declines across most regions. While the strategic initiatives like the Prysm iO intelligent wellness platform and expansion into India offer potential future growth drivers, their impact is yet to be realized and carries inherent execution risks. Given this mixed performance—operational efficiency and strategic optimism against ongoing declines in key business metrics—a 'hold' recommendation is appropriate until there is clearer evidence of a sustained turnaround driven by these new initiatives.

Keywords

Nu Skin, NUS, Q3 2025, earnings, financial results, intelligent wellness, Prysm iO, India expansion, direct selling, beauty, wellness, nutritional supplements, personal care, Pharmanex, ageLOC, Rhyz, SEC filing, 8-K